Avenzo to Present AVZO-023 Phase 1 Results at SABCS 2026
San Diego, California — October 30, 2026 Avenzo Therapeutics, Inc. announced that preliminary Phase 1 results from its ongoing...
Most Recent
Advertisement
Immunome Receives EMA Validation for Varegacestat Application
Bothell, Washington — October 30, 2026 Immunome, Inc. announced that the European Medicines Agency (EMA) has validated its Marketing...
Propanc Advances PPC-001 Assay Development for Phase 1b Cancer Study
Melbourne, Australia — October 30, 2026 Propanc Biopharma, Inc. announced progress in analytical development activities supporting its planned Phase...
Moleculin Completes MIRACLE Trial Part A Dosing in R/R AML
Houston, Texas — October 30, 2026 Moleculin Biotech, Inc. announced completion of patient dosing in Part A of its...
Atsena Reports Promising ATSN-301 Preclinical Data for Usher 1B
Durham, North Carolina — October 30, 2026 Atsena Therapeutics announced new preclinical findings for ATSN-301, an investigational dual adeno-associated...
Syndax’s Revuforj Wins 2026 Prix Galien Rare Disease Award
New York, New York — October 30, 2026 Syndax Pharmaceuticals, Inc. announced that Revuforj® (revumenib) has received the 2026...
Pelthos to Merge With Castle Creek, Expanding Skin Disease Pipeline
Durham, North Carolina and Exton, Pennsylvania — October 30, 2026 Pelthos Therapeutics Inc. and Castle Creek Biosciences, Inc. announced...
Denali Therapeutics Wins 2026 Prix Galien Award for AVLAYAH
South San Francisco, California — October 30, 2026 Denali Therapeutics Inc. announced that AVLAYAH® (tividenofusp alfa-eknm) has received the...
Setara Biosciences Raises $90M Series A to Advance Rare Disease Drugs
San Diego, California — October 30, 2026 Setara Biosciences, Inc. announced the completion of a $90 million Series A...
Alkermes Initiates Phase 2 Study of ALKS 7290 in Depression
Dublin, Ireland — October 30, 2026 Alkermes plc announced the initiation of a Phase 2 clinical study evaluating ALKS...
Advertisement
